Literature DB >> 1615923

The prognostic significance of proerythroblasts in acute erythroleukemia.

A Kowal-Vern1, J Cotelingam, H R Schumacher.   

Abstract

Erythroleukemia is a heterogeneous disorder that can have an excess of myeloblasts or proerythroblasts in the setting of dyserythropoiesis. The French-American-British classification, established in 1976 and subsequently revised, allows only for the diagnosis of erythroleukemias whose immature elements are predominated by myeloid blasts, previously described as DiGuglielmo's syndrome. However, there is another form of erythroleukemia, in which the predominant immature elements are proerythroblasts, called DiGuglielmo's disease. To clarify this issue, 23 cases of erythroleukemia were reviewed and classified: 10 with a myeloblast predominance and 13 with a proerythroblastic predominance. These two forms of erythroleukemia can be distinguished on the basis of quantitative and qualitative morphologic features. When there were 30% or more proerythroblasts, calculated by dividing the total erythroid component into the proerythroblasts, there were few to no myeloblasts, no Auer rods, and increased cytoplasmic vacuoles; and myeloperoxidase staining was negative. The malignant proerythroblasts had increased block and blush periodic acid-Schiff positivity. The most frequent chromosomal abnormalities involved chromosomes 5 and 7. The patients with DiGuglielmo's disease had a median survival time of 2 months (range, 0.06 to 9 months), compared to a median of 16 months (range, 2 to 48 months), in patients with DiGuglielmo's syndrome. The erythroleukemia with the preponderance of proerythroblasts had a worse prognosis because many of the individuals did not survive long enough to respond to the therapy initiated. Erythroleukemia with 30% or more proerythroblasts should be included in the French-American-British classification because it behaves clinically and appears morphologically as an acute leukemia rather than a myelodysplastic syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615923     DOI: 10.1093/ajcp/98.1.34

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Erythroleukaemia in the north of England: a population based study.

Authors:  A W Wells; N Bown; M M Reid; P J Hamilton; G H Jackson; P R Taylor
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

2.  Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6.

Authors:  F M Mazzella; H R Schumacher
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

Review 3.  Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6.

Authors:  R P Hasserjian; J Howard; A Wood; K Henry; B Bain
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

Review 4.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Authors:  Joseph D Khoury; Eric Solary; Oussama Abla; Yassmine Akkari; Rita Alaggio; Jane F Apperley; Rafael Bejar; Emilio Berti; Lambert Busque; John K C Chan; Weina Chen; Xueyan Chen; Wee-Joo Chng; John K Choi; Isabel Colmenero; Sarah E Coupland; Nicholas C P Cross; Daphne De Jong; M Tarek Elghetany; Emiko Takahashi; Jean-Francois Emile; Judith Ferry; Linda Fogelstrand; Michaela Fontenay; Ulrich Germing; Sumeet Gujral; Torsten Haferlach; Claire Harrison; Jennelle C Hodge; Shimin Hu; Joop H Jansen; Rashmi Kanagal-Shamanna; Hagop M Kantarjian; Christian P Kratz; Xiao-Qiu Li; Megan S Lim; Keith Loeb; Sanam Loghavi; Andrea Marcogliese; Soheil Meshinchi; Phillip Michaels; Kikkeri N Naresh; Yasodha Natkunam; Reza Nejati; German Ott; Eric Padron; Keyur P Patel; Nikhil Patkar; Jennifer Picarsic; Uwe Platzbecker; Irene Roberts; Anna Schuh; William Sewell; Reiner Siebert; Prashant Tembhare; Jeffrey Tyner; Srdan Verstovsek; Wei Wang; Brent Wood; Wenbin Xiao; Cecilia Yeung; Andreas Hochhaus
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

5.  Pure Erythroleukemia (Variant Acute Myeloid Leukemia-vAML-M6) with Deletion of Chromosome 20, Mainly Presenting as Late Erythroblasts, a Unique Case Report with Review of Literature.

Authors:  Javid Rasool; Sajad Geelani; Mohd Suhail Lone; Mohd Shaban
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-05       Impact factor: 0.900

6.  Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Authors:  F P S Santos; S Faderl; G Garcia-Manero; C Koller; M Beran; S O'Brien; S Pierce; E J Freireich; X Huang; G Borthakur; C Bueso-Ramos; M de Lima; M Keating; J Cortes; H Kantarjian; F Ravandi
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

Review 7.  Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

Authors:  Prajwal Boddu; Christopher B Benton; Wei Wang; Gautam Borthakur; Joseph D Khoury; Naveen Pemmaraju
Journal:  Blood Rev       Date:  2017-09-18       Impact factor: 8.250

8.  Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases.

Authors:  Hong Fang; Sa A Wang; Joseph D Khoury; Siba El Hussein; Do Hwan Kim; Mehrnoosh Tashakori; Zhenya Tang; Shaoying Li; Zhihong Hu; Fatima Zahra Jelloul; Keyur P Patel; Timothy J McDonnell; Tapan Kadia; L Jeffrey Medeiros; Wei Wang
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.